AMGN

Amgen
D

AMGN

Arincen67/100B

Amgen EPS (earnings per share) 1985–2026

Amgen's diluted EPS in Q3 FY2026, the three months to 30 September 2026, was 7.08 USD, up 19.4% on the same quarter a year before. Amgen's diluted earnings per share over the last twelve months were 17.24 USD, up 33.2% on the twelve months before. In fiscal year 2025 they were 14.23 USD, up 88.2% on the year before.

Last updated 12 Nov 2026 · Next report 2 Feb 2027

EPS

Growth

Fiscal yearPeriod endingEPSGrowthEPS (basic)
TTM30 Sept 202617.24+33.23%17.38
FY202531 Dec 202514.23+88.23%14.33
FY202431 Dec 20247.56-39.47%7.62
FY202331 Dec 202312.49+3.14%12.56
FY202231 Dec 202212.11+17.80%12.18
FY202131 Dec 202110.28-16.49%10.34
FY202031 Dec 202012.31-4.43%12.40
FY201931 Dec 201912.88+2.06%12.96
FY201831 Dec 201812.62+369.14%12.70
FY201731 Dec 20172.69-73.73%2.71
FY201631 Dec 201610.24+13.02%10.32
FY201531 Dec 20159.06+35.22%9.15
FY201431 Dec 20146.70+0.90%6.80
FY201331 Dec 20136.64+20.29%6.75
FY201231 Dec 20125.52+36.63%5.61
FY201131 Dec 20114.04-15.66%4.07
FY201031 Dec 20104.79+6.21%4.82
FY200931 Dec 20094.51+19.63%4.53
FY200831 Dec 20083.77+33.69%3.79
FY200731 Dec 20072.82+13.71%2.83
FY200631 Dec 20062.48-15.36%2.51
FY200531 Dec 20052.93+61.88%2.97
FY200431 Dec 20041.81+7.10%1.86
FY200331 Dec 20031.69—1.75
FY200231 Dec 2002-1.21-217.48%-1.21
FY200131 Dec 20011.03-1.90%1.07
FY200031 Dec 20001.05+2.94%1.11
FY199931 Dec 19991.02+24.39%1.07
FY199831 Dec 19980.82+38.98%0.85
FY199731 Dec 19970.59-3.28%0.61
FY199631 Dec 19960.61+29.79%0.61
FY199531 Dec 19950.47+67.86%0.48
FY199431 Dec 19940.28-20.00%0.29
FY199331 Dec 19930.35+12.90%0.35
FY199231 Dec 19920.31+244.44%0.31
FY199131 Dec 19910.09+200.00%0.09
FY199031 Dec 19900.03—0.03
FY198831 Dec 1988-0.01-655.56%-0.01
FY198731 Dec 19870.00+100.00%0.00
FY198631 Dec 19860.000.00%0.00
FY198531 Dec 19850.00—0.00

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

See also:Revenue,Net income,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Amgen's EPS

Source: Financial Modeling PrepVerified against SEC filings